Literature DB >> 26014046

Ninjin'yoeito and ginseng extract prevent oxaliplatin-induced neurodegeneration in PC12 cells.

Toshiaki Suzuki1, Ayano Yamamoto, Masahiro Ohsawa, Yoshiharu Motoo, Hajime Mizukami, Toshiaki Makino.   

Abstract

Ninjin'yoeito (NYT) is a formula of Japanese traditional kampo medicine composed of 12 crude drugs, and is designed to improve the decline in constitution after recovery from disease, fatigue, anemia, anorexia, perspiration during sleep, cold limbs, slight fever, chills, persistent cough, malaise, mental disequilibrium, insomnia, and constipation. Oxaliplatin (L-OHP) is a platinum-based anticancer drug used to treat colorectal, pancreatic, and stomach cancers. However, it often causes acute and chronic peripheral neuropathies including cold allodynia and mechanical hyperalgesia. In this study, we investigated the preventive effects of NYT on neuronal degeneration caused by L-OHP using PC12 cells, which are derived from the rat adrenal medulla and differentiate into nerve-like cells after exposure to nerve growth factor. L-OHP treatment decreased the elongation of neurite-like projection outgrowths in differentiated PC12 cells. When PC12 cells were treated with NYT hot water extract, neurodegeneration caused by L-OHP was significantly prevented in a concentration-dependent manner. Among the 12 crude drugs composing NYT, the extract of Ginseng (the root of Panax ginseng) exhibited the strongest preventive effects on neurodegeneration in differentiated PC12 cells. By activity-guided fractionation, we found that the fraction containing ginsenosides displayed preventive activity and, among several ginsenosides, ginsenoside F2 exhibited significant preventive effects on L-OHP-induced decreases in neurite-like outgrowths in differentiated PC12 cells. These results suggest that NYT and ginseng are promising agents for preventing L-OHP-induced neuropathies and present ginsenoside F2 as one of the active ingredients in ginseng.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26014046     DOI: 10.1007/s11418-015-0921-9

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  17 in total

Review 1.  Oxaliplatin-related neurotoxicity: how and why?

Authors:  Lara Maria Pasetto; Mario Rosario D'Andrea; Elena Rossi; Silvio Monfardini
Journal:  Crit Rev Oncol Hematol       Date:  2006-06-27       Impact factor: 6.312

Review 2.  Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?

Authors:  V A Carozzi; A Canta; A Chiorazzi
Journal:  Neurosci Lett       Date:  2014-10-22       Impact factor: 3.046

3.  Bioactivity and bioavailability of ginsenosides are dependent on the glycosidase activities of the A/J mouse intestinal microbiome defined by pyrosequencing.

Authors:  Tao Niu; Diane L Smith; Zhen Yang; Song Gao; Taijun Yin; Zhi-Hong Jiang; Ming You; Richard A Gibbs; Joseph F Petrosino; Ming Hu
Journal:  Pharm Res       Date:  2012-12-20       Impact factor: 4.200

4.  Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.

Authors:  C Qvortrup; M Yilmaz; D Ogreid; A Berglund; L Balteskard; J Ploen; T Fokstuen; H Starkhammar; H Sørbye; K Tveit; P Pfeiffer
Journal:  Ann Oncol       Date:  2008-02-14       Impact factor: 32.976

5.  Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice.

Authors:  Masahiro Ohsawa; Saki Otake; Tomoyasu Murakami; Shohei Yamamoto; Toshiaki Makino; Hideki Ono
Journal:  J Pharmacol Sci       Date:  2014-07-03       Impact factor: 3.337

6.  Neurite outgrowth induced by spicatoside A, a steroidal saponin, via the tyrosine kinase A receptor pathway.

Authors:  Jinyoung Hur; Pyeongjae Lee; Eunjung Moon; Insug Kang; Sung-Hoon Kim; Myung Sook Oh; Sun Yeou Kim
Journal:  Eur J Pharmacol       Date:  2009-08-18       Impact factor: 4.432

7.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Authors:  Sophie Gourgou-Bourgade; Caroline Bascoul-Mollevi; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Valérie Boige; Jocelyne Bérille; Thierry Conroy
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Authors:  Yasuhide Yamada; Daisuke Takahari; Hiroshi Matsumoto; Hideo Baba; Masato Nakamura; Kazuhiro Yoshida; Motoki Yoshida; Shigeyoshi Iwamoto; Ken Shimada; Yoshito Komatsu; Yasutsuna Sasaki; Taroh Satoh; Keiichi Takahashi; Hideyuki Mishima; Kei Muro; Masahiko Watanabe; Yuh Sakata; Satoshi Morita; Yasuhiro Shimada; Kenichi Sugihara
Journal:  Lancet Oncol       Date:  2013-11-11       Impact factor: 41.316

Review 10.  Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors.

Authors:  Seung-Yeol Nah
Journal:  Front Physiol       Date:  2014-03-19       Impact factor: 4.566

View more
  8 in total

1.  Effect of ninjin'yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice.

Authors:  Toshiaki Suzuki; Ayano Yamamoto; Masahiro Ohsawa; Yoshiharu Motoo; Hajime Mizukami; Toshiaki Makino
Journal:  J Nat Med       Date:  2017-07-10       Impact factor: 2.343

2.  Ginsenosides, ingredients of the root of Panax ginseng, are not substrates but inhibitors of sodium-glucose transporter 1.

Authors:  Shengli Gao; Hirotaka Kushida; Toshiaki Makino
Journal:  J Nat Med       Date:  2016-09-12       Impact factor: 2.343

3.  Long-term maintenance of nutritional status with ninjinyoueito in terminal patients with chronic respiratory disease: Two case reports.

Authors:  Yuika Sasatani; Shinichiro Okauchi; Gen Ohara; Katsunori Kagohashi; Hiroaki Satoh
Journal:  Biomed Rep       Date:  2019-12-20

4.  Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells.

Authors:  Shun Takaku; Masumi Shimizu; Hidemi Takahashi
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

5.  Postoperative Adjuvant Chemotherapy Regimen of CAPOX Combined With Ninjin'yoeito in an Elderly Patient With Stage III Colon Cancer: A Case Report.

Authors:  Naoki Aomatsu; Yasutake Uchima; Gen Tsujio; Yoshinari Miyamoto; Takuma Okada; Shigeaki Kurihara; Shinji Matsutani; Toshiki Hirakawa; Takehiko Iwauchi; Junya Morimoto; Shigehito Yamagata; Kazunori Nakazawa; Takafumi Nishii; Akiko Tachimori; Kiyoshi Maeda; Katsumi Ikeda; Kazuhiro Takeuchi
Journal:  Front Nutr       Date:  2020-04-30

Review 6.  Application Potential of Plant-Derived Medicines in Prevention and Treatment of Platinum-Induced Peripheral Neurotoxicity.

Authors:  Xiaowei Xu; Liqun Jia; Xiaoran Ma; Huayao Li; Changgang Sun
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

7.  Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients.

Authors:  Zhi-Ying Chen; Yue Liu; Yuan Wei; Lin-Yao Deng; Qiang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-22       Impact factor: 2.650

Review 8.  Multifunctional Actions of Ninjinyoeito, a Japanese Kampo Medicine: Accumulated Scientific Evidence Based on Experiments With Cells and Animal Models, and Clinical Studies.

Authors:  Kanako Miyano; Miki Nonaka; Miaki Uzu; Kaori Ohshima; Yasuhito Uezono
Journal:  Front Nutr       Date:  2018-10-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.